Could a common blood thinner replace warfarin for tricky heart valve patients?
NCT ID NCT04045093
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares dabigatran (Pradaxa) to warfarin for preventing strokes in 370 people with both atrial fibrillation and moderate-to-severe mitral stenosis. Participants are randomly assigned to one of the two blood thinners. The goal is to see if dabigatran is as good as or better than warfarin at preventing strokes, blood clots, heart attacks, and death, while possibly having fewer side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dabigatran etexilate (Pradaxa)
What this could lead to
If successful, this could provide a safer, more convenient alternative to warfarin for stroke prevention in atrial fibrillation patients with mitral stenosis.
What could go wrong
This is a relatively small, open-label trial, and results may not apply to all patients. Dabigatran may not be as effective or safe as warfarin in this specific population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Hong Kong / Queen Mary Hospital
Hong Kong, Hong Kong